S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Avoro Capital Advisors/Q1 2025

Avoro Capital Advisors

Period: Q1 2025 Β· Filed: 2025-05-15
View on SEC EDGAR β†—
AUM
$6.41B
Total portfolio value
Positions
33
Reported securities
Top Holding
UTHR
12.9% $824.6M
QoQ Changes
+1 / -7
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-05-15) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
UTHRUNITED THERAPEUTICS CORP$824.6M12.87%$308.27$555.91+80.3%
12.9%
ASNDASCENDIS PHARMA$813.3M12.69%$155.86$274.50+76.1%
12.7%
ARGXARGENX SE$731.1M11.41%$591.86$939.68+58.8%
11.4%
MDGLMADRIGAL PHARMACEUTICALS INC$669.8M10.46%$331.23$528.10+59.4%
10.5%
KRYSKRYSTAL BIOTECH INC$492.4M7.69%$180.30$375.07+108.0%
7.7%
BPMCBLUEPRINT MEDICINES CORP$340.8M5.32%β€”β€”
5.3%
APLSAPELLIS PHARMACEUTICALS INC.$267.3M4.17%$21.87β€”
4.2%
RNAMAVIDITY BIOSCIENCES INC$225.1M3.51%β€”β€”
3.5%
XENEXENON PHARMACEUTICALS INC$192.6M3.01%$33.55$60.96+81.7%
3.0%
SLNOSOLENO THERAPEUTICS INC$180.4M2.82%$71.45β€”
2.8%
KYMRKYMERA THERAPEUTICS INC$176.8M2.76%$27.37$113.51+314.7%
2.8%
SRPTSAREPTA THERAPEUTICS INC$170.7M2.66%$63.82$19.28-69.8%
2.7%
FOLDAMICUS THERAPEUTICS INC.$167.3M2.61%β€”β€”
2.6%
ARWRARROWHEAD PHARMACEUTICALS INC.$141.6M2.21%$12.74$83.99+559.3%
2.2%
VERAVERA THERAPEUTICS INC$137.0M2.14%$24.02$41.20+71.5%
2.1%
MRUSMERUS N V$126.3M1.97%β€”β€”
2.0%
MLTXMOONLAKE IMMUNOTHERAPEUTICS$108.2M1.69%$39.07$18.95-51.5%
1.7%
ITCIINTRA-CELLULAR THERAPIES INC$82.5M1.29%β€”β€”
1.3%
ALKSALKERMES PLC$80.9M1.26%$33.02$54.58+65.3%
1.3%
BCRXBIOCRYST PHARMACEUTICALS INC$65.3M1.02%$7.50$9.84+31.2%
1.0%
OCULOCULAR THERAPEUTIX INC$59.1M0.92%$7.33$9.64+31.5%
0.9%
CNTACENTESSA PHARMACEUTICALS PLC$58.2M0.91%$14.38$40.50+181.6%
0.9%
ETNB89BIO INC$46.2M0.72%β€”β€”
0.7%
MNKDMANNKIND CORP$44.0M0.69%$5.03$4.52-10.1%
0.7%
PCVXVAXCYTE INC$37.8M0.59%$37.76$58.39+54.6%
0.6%
TRMLTOURMALINE BIO INC$36.9M0.58%β€”β€”
0.6%
RAREULTRAGENYX PHARMACEUTICAL INC$30.1M0.47%$36.21$33.47-7.6%
0.5%
TSHATAYSHA GENE THERAPIES INC$27.8M0.43%$1.39$6.53+369.8%
0.4%
QUREUNIQURE NV$23.1M0.36%$10.60$41.81+294.4%
0.4%
GLUEMONTE ROSA THERAPEUTICS INC$21.6M0.34%$4.64$24.21+421.8%
0.3%

Quarter-on-Quarter Activity

Q1 2025 vs. Q4 2024

New Positions (1)

TickerIssuerNotionalSince Filing
CNTACENTESSA PHARMACEUTICALS PLC$58.2M+181.6%

Exited Positions (7)

TickerIssuerNotional
BMRNBIOMARIN PHARMACEUTICAL INC$96.1M
SNDXSYNDAX PHARMACEUTICALS INC$30.1M
IOVAIOVANCE BIOTHERAPEUTICS INC$25.9M
CGONCG ONCOLOGY INC$20.1M
KURAKURA ONCOLOGY INC$19.6M
RCKTROCKET PHARMACEUTICALS INC$15.1M
OLMAOLEMA PHARMACEUTICALS INC$9.6M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
BPMCBLUEPRINT MEDICINES CORP$237.4M+224.9%
ETNB89BIO INC$14.1M+54.9%
MRUSMERUS N V$36.9M+41.2%
KYMRKYMERA THERAPEUTICS INC$-30.4M+25.4%+314.7%
SEPNSEPTERNA INC$-17.7M+20.5%
TRMLTOURMALINE BIO INC$-8.2M+9.1%
GLUEMONTE ROSA THERAPEUTICS INC$-8.6M+6.9%+421.8%
SRPTSAREPTA THERAPEUTICS INC$-140.0M+4.7%-69.8%

Trimmed (7)

TickerIssuerNotionalShares Ξ”Since Filing
ITCIINTRA-CELLULAR THERAPIES INC$-172.3M-79.5%
BCRXBIOCRYST PHARMACEUTICALS INC$-24.0M-26.7%+31.2%
PCVXVAXCYTE INC$-58.4M-14.9%+54.6%
FOLDAMICUS THERAPEUTICS INC.$-51.0M-11.5%
UTHRUNITED THERAPEUTICS CORP$-149.3M-3.1%+80.3%
MDGLMADRIGAL PHARMACEUTICALS INC$43.7M-0.3%+59.4%
ARGXARGENX SE$-30.6M-0.3%+58.8%
← Back to Hedge Funds